Equities

J L Morison Sons & Jones (Ceylon) PLC

J L Morison Sons & Jones (Ceylon) PLC

Actions
Consumer GoodsHousehold Goods
  • Price (LKR)351.20
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change6.42%
  • Beta1.5217
Data delayed at least 15 minutes.
More ▼

Profile data is unavailable for this security.

About the company

J.L. Morison Son & Jones (Ceylon) PLC is a holding company. The Company is engaged in importing and distribution of pharmaceuticals, agro chemicals, medical aid, hair care products, diagnostics reagent and equipment, and other consumer products, and manufacturing and trading in pharmaceuticals and cosmetics. The Company's segments include consumer, agrochemicals and pharmaceuticals. In addition to manufacturing pharmaceutical and over-the-counter (OTC) products, the Company also imports and distributes healthcare, consumer and agro brands through its island distribution network. The Company's OTC and consumer category includes brands, such as Morison's Lacto Calamine, Morison's Gripe Mixture and Valmelix Cough Syrup. The Company is a subsidiary of Hemas Manufacturing (Pvt) Ltd. The Company's subsidiary is M.S.J. Industries (Ceylon) (Private) Limited.

  • Revenue in LKR (TTM)3.86bn
  • Net income in LKR384.72m
  • Incorporated2007
  • Employees--
  • Location
    J L Morison Sons & Jones (Ceylon) PLC620, Biyagama Road, PethiyagodaKELANIYA Sri LankaLKA
  • Phone+94 112904222Fax+94 112915378
  • Websitehttp://www.jlmorisons.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Elanix Biotechnologies AG0.00-10.18k21.94m0.00--7.73-----0.0197-0.01970.000.5010.00-------2.34-10.76-3.68-10.85-------7,803.41---29.850.00------88.01------
Probiotec Limited65.61m2.34m23.82m111.0010.180.5459--0.3630.04420.07581.240.82440.92294.387.70--3.291.494.652.2036.5539.523.572.140.54525.560.14611.223.63-1.782,585.07---1.96--
Unipharm AD17.28m444.00k24.60m258.0055.411.4210.281.420.0740.0742.882.900.84473.344.11--2.175.692.366.4546.7848.312.576.773.49--0.056170.551.36-0.12-37.09-1.56-20.942.43
Jagsonpal Pharmaceuticals Ltd1.54bn34.95m937.89m--27.060.942514.210.60821.321.3258.3537.980.95711.493.60--2.172.063.443.1361.0551.632.272.061.061.910.12934.744.29-2.19177.88-14.64-17.07-27.52
Ind Swift Laboratories Limited3.16bn334.55m1.63bn915.002.23--3.920.516816.3716.37157.60-------------2.95---4.2929.6424.1510.61-6.75--4.55-----1.09-9.0150.83---27.90--
J.L.Morison, Sons & Jones (Ceylon) Ltd.3.86bn384.72m2.48bn--6.400.87525.550.643750.9550.95511.16372.480.97283.794.99--9.707.8412.6410.1334.8631.359.977.602.13--0.14714.5122.775.9942.1213.5738.96--
Data as of --. Currency figures normalised to J L Morison Sons & Jones (Ceylon) PLC's reporting currency: Sri Lankan Rupee LKR
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.